NASDAQ looks bullish, the new quarter has kicked in Seasonal Tendacies suggest higher price
US30 looks bullish, the new quarter has kicked in Seasonal Tendacies suggest higher price
The VIX Angry Crab is about to make its move, and it’s ready to pinch! Starting from a cozy 18, this volatile crustacean is eyeing its next targets: TP1, TP2, and TP3. Whether it’s a scuttle upward or a sideways shuffle, traders beware—this crab doesn’t just crawl, it spikes! Keep your stop-loss nets ready and your trading claws sharp because when the Angry Crab gets riled up, it’s not just a market indicator; it’s a market mood swing. As always, make your decisions wisely—after all, even the boldest crab can sometimes get caught in a tide. SEYED.
The new quarter has kicked in . DXY is looking bullish Seasonal Tendacies are suggesting higher prices There's been a Change of character
Market news: In the early Asian session on Tuesday (March 25), spot gold fluctuated narrowly and is currently trading around $3,012 per ounce. London gold prices fell 0.4% on Monday, falling to $3,002 per ounce during the session. The US dollar hit its highest level in more than two weeks, prompting more gold bulls to take profits, and investors to assess US President Trump's more cautious stance on imposing tariffs on trading partners. Since 2025, gold prices have risen by about 15% in total, breaking the $3,000 per ounce mark for the first time. According to officials familiar with the matter, the Trump administration's tariff plan may be more targeted rather than the comprehensive, global taxation previously envisioned. This adjustment is expected to ease inflationary pressures and increase room for future interest rate cuts, which is beneficial to international gold, an interest-free asset. The total number of new home sales in the United States in February and the US Conference Board Consumer Confidence Index in March will be released on this trading day, and investors need to pay attention to them. In addition, it is necessary to pay attention to the speeches of Federal Reserve officials. Technical Review: Yesterday, gold surged and fell back, closing with a middle-yin line with upper and lower shadows. After the overall rebound, it continued to fall. The daily line retreated with a continuous negative structure, and the RSI indicator turned downward. The price retreated and the MA10 daily moving average was lost again and continued to fall. The price of the four-hour chart and the hourly chart runs along the middle and lower tracks of the Bollinger Bands. On the 4-hour level trend, the K-line currently basically maintains a good oscillating downward trend along the short-term moving average. The current rebound has basically completed the technical form repair. Pay attention to the possible secondary decline trend after the rebound repair is completed. In the short-term trend, it is currently slightly stronger, and pay attention to the short-term adjustment. Today's analysis: The current gold daily chart shows that the gold price has reached the top and retreated, and the Bollinger Bands are running open, but the gold price is still running at a high level. The KDJ indicator on the disk is glued to the upper overbought area to form a dead cross. On Monday, the gold price did not clearly indicate the direction of rise and fall, and it was more in a consolidation pattern. It is recommended to pay attention to the pressure and support of the MA5 and MA10 moving averages in the range of 3035-3000 US dollars, and try to follow the trend to see more or less.The 4-hour chart of gold shows that the resistance point of the SAR indicator has moved down to the vicinity of 3035 US dollars, and the overlap with the daily MA5 moving average has formed a double suppression in the short term. If the bulls want to restart, they still need to break through this position strongly. The lower track of the hourly Bollinger band is 3000 and the lower track of the 1-hour Bollinger band is 2992. The downward deviation looks at the 3000 integer mark. If the entity falls below the 3000 mark, refer to the low point of last week at 2981 and the weekly MA5 moving average support point of 2960. The trading ideas and direction remain unchanged. Maintain the high-altitude band layout as the main, and assist with low-multiple short-term! Operation ideas: Short-term gold 2990-2993 buy, stop loss 2982, target 3020-3030; Short-term gold 3027-3030 sell, stop loss 3038, target 3000-2990; Key points: First support level: 3002, second support level: 2993, third support level: 2980 First resistance level: 3018, second resistance level: 3030, third resistance level: 3046
Currently price has entered the medium risk zone. Price has shown signs of rejections in the smaller timeframe. This should be additional confluence for me to participate in the market as there is a potential CHOCH in the smaller timeframe. In this trade I am only participating base on market structure and fibonacci retracement
BTC tapped into a clean POI zone after sweeping highs. A market structure shift (MSS) formed, showing early signs of bearish intent. Price is now reacting from the zone, and we’ve mapped the clean flow toward the 2H demand base. Invalidation is clearly marked — a clean break above 88,005 would flip the bias. Precise POI, projection, and target laid out. — CelestiaPips
?? ? Asset: MSTX (NASDAQ) ? Timeframe: 30-Min Chart ? Setup Type: Bullish Breakout from Ascending Triangle / Wedge Pattern ? Trade Plan (Long Position) ✅ Entry Zone: Above $35.84 (Confirmed breakout level) ✅ Stop-Loss (SL): Below $32.18 (Wedge base & structure support) ? Take Profit Targets: ? TP1: $39.58 (Major resistance zone) ? TP2: $44.77 (Extended target from pattern projection) ? Risk-Reward Ratio Calculation: ? Risk (SL Distance): $35.84 - $32.18 = $3.66 risk per share ? Reward to TP1: $39.58 - $35.84 = $3.74 (1.02:1 R/R) ? Reward to TP2: $44.77 - $35.84 = $8.93 (2.44:1 R/R) ? Technical Analysis & Strategy ? Ascending Wedge Breakout: Price broke resistance of tightening structure — bullish signal. ? Momentum Shift: Big green candles and volume spike indicate buyer strength. ? Retest Opportunity: Entry near $35.84 is ideal as price retests breakout zone. ? Clear Resistance Zones Above: Targets marked at key historical levels for precision. ⚙️ Trade Execution & Risk Management ? Volume Confirmation: Make sure bullish volume sustains above $35.84. ? Trailing Stop Strategy: Once TP1 ($39.58) is hit, move SL to entry ($35.84) to lock in gains. ? Partial Profit Booking Strategy ✔ Book 50% of profits at TP1 ($39.58) ✔ Let remaining ride to TP2 ($44.77) ✔ Adjust stop-loss to breakeven or higher after TP1 ⚠️ Breakout Failure Risk ❌ Do not enter if price closes back below $35.84 ❌ Close position if $32.18 is broken — setup is invalid ? Final Thoughts ✔ Strong breakout setup with healthy volume confirmation ✔ Clear bullish structure with great follow-through potential ✔ High-probability trade offering 2.44:1 R/R to TP2 — manage smartly! ? #MSTX #NASDAQ #LongTrade #ETFTrading #BreakoutSetup #ProfittoPath ??
My setup base on fibo zone and supply and demand zone from H1 to H4
The deteriorating sentiment over the last 3 years has created a substantial buying opportunity. The negative sentiment can be attributed to 4 main things- decreased EPS/ Net Income since 2022/2023 (end of COVID $$), increased debt levels post-Seagen acquisition and revenue challenges due to upcoming patent expirations. While these concerns are not unwarranted, it is important to note that Pfizer has been through several patent cliffs before while simultaneously growing dividends . The notable upcoming expirations include the pneumonia shot Prevnar in 2026 and the cancer drugs Ibrance and Xtandi, both in 2027. Pfizer has an exceptional history of capital preservation and therefore will continue to take action to address any potential revenue shortfalls including aggressive cost-cutting measures already in progress. From a valuation perspective, PFE's shiller PE is currently 9.51 or 94% as low as it has been in the last 10 years and also 89% better than 462 companies in the drug manufacturing industry. Seeking Alpha gives PFE a grade of F on Growth, but when looking at the individual characteristics not 1 is below a D and only two are D's, and in aggregate looks much better than SA is portraying with a grade of F. Pfizer should not usually be expected to be a grower as it is a mature company. From a technical standpoint it looks like a double bottom is forming at the bottom of a 12 year trend line. The Price/ FCF and EV/EBITDA ratios have decreased back to 2023 and prior levels indicating it is no longer overvalued as it was in 2024. Reverse DCF based on EPS w/out NRI and an 11% discount rate show thaf Pfizer's fair value is $35.89, indicating a 27% margin of safety. The recent volume shows large-scale buying, probably by institutions. Overall I believe the negative sentiment mostly due to the upcoming patent expiration and the realization of loss of revenue from COVID era $ is currently baked into the price and presents a decent buying opportunity.